This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

H. Friedman, MD; D. J. Greenblatt, MD

JAMA. 1986;256(16):2227-2233.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

FOR MANY drugs, the measurement of concentrations in serum or plasma has become widely available and accepted as an important component of clinical decision making. While these drug levels often do allow more objective monitoring and titration of therapy, the information also has the potential to be valueless or even misleading. Laboratories sometimes report that a serum concentration is in the "toxic" range, when the patient is doing well and has no evidence of toxic effects. Or, conversely, the drug is not detectable in serum. Such discrepancies between measured serum drug concentrations and observed clinical drug effects may occur for numerous reasons. This article will review some principles and problems associated with therapeutic drug monitoring.

RATIONALE FOR MONITORING SERUM DRUG LEVELS

For a serum drug concentration to be potentially useful for purposes of therapeutic monitoring, at least two requisites must be fulfilled.¹ First, the serum drug concentration must reflect . . . [Full Text PDF of this Article]

Author Affiliations
From the Division of Clinical Pharmacology, Departments of Psychiatry and Medicine, Tufts University School of Medicine and New England Medical Center, Boston.

Footnotes
Reprint requests to Division of Clinical Pharmacology, Box 1007, Tufts-New England Medical Center, 171 Harrison Ave, Boston, MA 02111 (Dr Greenblatt).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?